Drugs / OPDC-34712
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01074294 | Mar 2010 → Jun 2011 | attention deficit-hyperactivity disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPDC-34712 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01074294 ↗ |
| Route | Oral | “OPDC-34712 tablets, daily, Orally.” NCT01074294 ↗ |